NCT00433745View on ClinicalTrials.gov

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Myelodysplastic SyndromeAcute Myeloid Leukemia (AML)Chronic Myeloid Leukemia (CML)
Interventions
DRUG

WT1 Peptide Vaccine

WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)

Trial Locations (1)

20892

National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00433745 - Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | Biotech Hunter | Biotech Hunter